If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A Spanish research group of the public health system has developed a new therapy for the treatment or prevention of GVHD through a kit composed of an immunosuppressive agent and mesenchymal stromal cells of adipose tissue. The therapy improves and facilitates the processing and accessibility of the donor tissue.
A license agreement or a technical cooperation agreement for a public or private partnership for the further development of the patented technology is sought.
Graft versus host disease (GVHD) is a condition that might occur after an allogeneic transplant. In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body.
Treatment often cannot provide complete healing and it takes a long time to cure the disease. The Spanish research group has developed a new therapy using mesenchymal stromal cells which improves and facilitates the processing and accessibility of the donor tissue.
Mesenchymal stromal cells are commonly known for their immunomodulatory effects, hence their interest in treating GVHD after a transplant of hematopoietic stem cells.
The Spanish research group has developed a kit composed of an immunosuppressive agent and mesenchymal stromal cells of adipose tissue.
This method helps to reduce the unwanted effects of it, such as the high probability of relapse, infections or delay for recovering the immune system.
The research group is looking for the following collaboration:
-License agreement: framework of authorizing the interested parties to use the technology.
-Technical cooperation agreement: to collaborate with other research teams, companies or foundations.
- The use of mesenchymal stromal cells derived from adipose tissue improves and facilitates the processing and accessibility of the donor tissue.
- Higher cellular performance.
- More genetic stability.
-There are illustrative examples and clinical evidences that show the nature of the technique.
PCT patent application
The research group aims to formalize a technology transfer process with public or private entities interested in the implementation of the solution, through a license agreement.
If there are some entities, such as R&D centres, technology centres or specialized companies, interested in collaborating and developing further aspects of the solution, a technical cooperation agreement could be envisaged.
They already sell the plate in Spain and now they want to expand abroad.